Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
219
Views
1
CrossRef citations to date
0
Altmetric
Correspondence

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Lina van der StratenDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-9359-1203
ORCID Icon,
Avinash G. DinmohamedDepartment of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; ;Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands; ;Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-4767-6716
ORCID Icon,
Peter E. WesterweelDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;
,
Anton W. LangerakDepartment of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands;
,
Jurgen RiedlDepartment of Clinical Chemistry, Result laboratories, Albert Schweitzer Hospital, Dordrecht, The Netherland;
,
Jeanette K. DoorduijnDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
,
Arnon P. KaterDepartment of Hematology, Academic Medical Centre, Amsterdam, the Netherlands
&
Mark-David LevinDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;
show all
Pages 2757-2761 | Received 09 Nov 2017, Accepted 25 Feb 2018, Published online: 04 Apr 2018

References

  • Lee LJ, Toze CL, Huang SJ, et al. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada. Leuk Lymphoma. 2018 [cited 2017 Oct 16]; [8 p.]. DOI:10.1080/10428194.2017.1387904
  • Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria-balancing patient protection and participation in oncology trials. N Engl J Med. 2017;376:1504–1505.
  • Goede V, Busch R, Bahlo J, et al. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leuk Lymphoma. 2016;57:596–603.
  • Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
  • Cramer P, Isfort S, Bahlo J, et al. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica. 2015;100:1451–1459.
  • R Core Team. R: a language and environment for statistical computing Vienna, Austria: R: Foundation for Statistical Computing; 2016. Available from: https://www.R-project.org/
  • Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–1765.
  • Takei K, Yamazaki T, Sawada U, et al. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leuk Res. 2006;30:625–631.
  • Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–3908.
  • Marquez ME, Hernández‐Uzcátegui O, Cornejo A, et al. Bone marrow stromal mesenchymal cells induce down regulation of CD20 expression on B‐CLL: implications for rituximab resistance in CLL. Br J Haematol. 2015;169:211–218.
  • Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007;110:2811–2818.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.